Kevin eggan dating
'Our continued collaboration is based upon a shared vision to match world-class science with industrial capability to address important unmet medical need, which is at the core of our public mission.' Evotec has also reached an agreement in principal with Patients Like Me ( on approaches to rapidly evaluate any patient testable theories about progression or pathways that might express themselves in ALS patients. ABOUT ALSAmyotrophic lateral sclerosis ('ALS') - also referred to as motor neurone disease or Lou Gehrig's disease in some part of the United States - is a debilitating disease with varied etiology characterised by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia) and difficulty breathing (dyspnea).
ALS is the most common of the five motor neuron diseases.
'Evotec, HSCI and Harvard share a commitment to accelerating promising research from the lab to the clinic', says Isaac T.
Kohlberg, Harvard University's Senior Associate Provost and Chief Technology Development Officer.
The collaboration 'Cure) will leverage human motor neuron assays based on ALS patient-derived induced pluripotent stem ('i PS') cells that were developed by Dr Lee Rubin, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard, and Dr Kevin Eggan, Early Career Scientist at the Howard Hughes Medical Institute, HSCI Principal Faculty member and professor in the Department of Stem Cell and Regenerative Biology at Harvard as well as Evotec's leading drug discovery infrastructure and expertise to identify compounds that will have therapeutic value against this life-threatening disease.Our intention is to systematically screen for new mechanisms, targets and compounds that have the potential to be developed into new products that will modify and ideally halt the progression of ALS and potentially other motor neuron diseases.' 'Phenotypic screens based on patient-derived i PS cells are an exciting approach to tackle diseases where tractable mechanisms have remained elusive.Evotec's proven expertise in high-content screening and deep knowledge in the field of motor neurons is a perfect match for this project.The disorder induces muscle weakness and atrophy throughout the body caused by the degeneration of the upper and lower motor neurons.
This partnership model efficiently and effectively drives the development of innovative drug candidates.
'This agreement is another important step in our vital collaboration with Evotec, enabling us to hasten the transfer of stem cell-based discoveries to the clinic', said Brock Reeve, Executive Director of HSCI.